A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Margetuximab (Primary) ; Capecitabine; Eribulin; Gemcitabine; Trastuzumab; Vinorelbine
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms SOPHIA
- Sponsors MacroGenics
- 22 Jun 2017 Planned End Date changed from 1 May 2018 to 1 Mar 2021.
- 22 Jun 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Mar 2020.
- 10 Jun 2017 Biomarkers information updated